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Abstract: Human mouse double minute 2 (Mdm2) plays an essential role in the regulation of the tumor
suppressor p53. The G/G variant of SNP309 was shown to increase Mdm2 mRNA/protein expression
and to be associated with an increased risk and earlier onset of different cancers in Asian populations.
However, the frequency and impact of these G/G variants have not been studied in Caucasian renal
cell carcinoma (RCC) patients. Therefore, we analyzed an unselected German cohort of 197 consecutive
RCC patients and detected the G/G variant in 18 (9.1%) patients, the G/T variant in 116 (58.9%)
patients and the T/T variant in 63 (32.0%) patients. Studying the association between age at tumor
onset and SNP309 genotypes, no correlation was detected in the entire RCC cohort or among the male
RCC patients. However, the female G/G patients (median age 59.5 years) were diagnosed 13.5 years
earlier than the T/T females (median age 73 years). When separating all females into two groups at
their median age (68 years), 7 and 1 patients with the G/G variant and 9 and 13 patients with the T/T
variant were noted in these age groups (P=0.024). To study the age dependency of tumor onset further,
a second, age-selected cohort of 205 RCC patients was investigated, which comprised especially young
and old patients. Interestingly, the G/G type occurred more often at lower tumor stages and tumor
grades compared with higher stages (P=0.039 and 0.004, respectively). In females, the percentage of
the G/G variant was only slightly higher in the younger age group, whereas in males, the percentage of
the G/G variant was remarkably higher in the younger age group (19.4% vs 8.0%). In summary, female
Caucasian RCC patients with the MDM2 SNP309 G/G genotype showed significantly earlier tumor onset
than patients with the wild-type T/T genotype.
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OPEN
SHORT COMMUNICATION
Homozygous G/G variant of SNP309 in the human MDM2
gene is associated with earlier tumor onset in Caucasian female
renal cell carcinoma patients
CG Stoehr1, R Stoehr1, A Wenners2, A Hartmann1, S Bertz1, V Spath3, B Walter4,5, K Junker6, H Moch7, R Hinze8, S Denzinger9, EE Bond10,
GL Bond10, K Bluemke11, K Weigelt4, V Lieb4, E Nolte4, P Fornara12, B Wullich4, H Taubert4,13 and S Wach4,13
Human mouse double minute 2 (Mdm2) plays an essential role in the regulation of the tumor suppressor p53. The G/G variant of
SNP309 was shown to increase Mdm2 mRNA/protein expression and to be associated with an increased risk and earlier onset of
different cancers in Asian populations. However, the frequency and impact of these G/G variants have not been studied in
Caucasian renal cell carcinoma (RCC) patients. Therefore, we analyzed an unselected German cohort of 197 consecutive RCC
patients and detected the G/G variant in 18 (9.1%) patients, the G/T variant in 116 (58.9%) patients and the T/T variant in 63 (32.0%)
patients. Studying the association between age at tumor onset and SNP309 genotypes, no correlation was detected in the entire
RCC cohort or among the male RCC patients. However, the female G/G patients (median age 59.5 years) were diagnosed 13.5 years
earlier than the T/T females (median age 73 years). When separating all females into two groups at their median age (68 years),
7 and 1 patients with the G/G variant and 9 and 13 patients with the T/T variant were noted in these age groups (P = 0.024).
To study the age dependency of tumor onset further, a second, age-selected cohort of 205 RCC patients was investigated, which
comprised especially young and old patients. Interestingly, the G/G type occurred more often at lower tumor stages and tumor
grades compared with higher stages (P= 0.039 and 0.004, respectively). In females, the percentage of the G/G variant was only
slightly higher in the younger age group, whereas in males, the percentage of the G/G variant was remarkably higher in the
younger age group (19.4% vs 8.0%). In summary, female Caucasian RCC patients with the MDM2 SNP309 G/G genotype showed
signiﬁcantly earlier tumor onset than patients with the wild-type T/T genotype.
Oncogenesis (2016) 5, e205; doi:10.1038/oncsis.2016.15; published online 29 February 2016
INTRODUCTION
The human mouse double minute 2 (Mdm2) gene/protein
interacts with the tumor suppressor p53 in a negative
auto-regulatory feedback loop.1 In humans, MDM2 has been
shown to be overexpressed in several tumors and is associated
with accelerated cancer progression and a lack of response
to therapy in some tumor entities and cancer cell lines.2–6
Bond and co-workers7 suggested that elevated Mdm2
RNA and protein levels may be caused by a single-nucleotide
polymorphism (SNP309 T4G; rs2279744) in the P2 promoter of
the Mdm2 gene, which may increase the DNA-binding
afﬁnity of the SP1 transcription factor. An eightfold higher
level of MDM2 mRNA was found in G/G genotype cells
compared with T/T cells in a panel of cell lines.7 Cells with
homozygous genotypes (TT4GG) for MDM2 SNP309 and wild-
type p53 differed by an average of ﬁvefold in their respective drug
sensitivities.8
A signiﬁcant effect on age of cancer diagnosis (tumor onset) has
already been shown for individuals with Li-Fraumeni syndrome in
female patients with soft tissue sarcomas, diffuse large B-cell
lymphomas, invasive ductal breast carcinoma and colorectal
cancer.7,9,10 However, in several studies on breast cancer and
lung cancer, MDM2 SNP309 was not associated with increased
MDM2 protein expression or increased cancer risk.11–14 There are
two factors that can inﬂuence the effect of the SNP309G/G
genotype as follows: estrogen receptor status, which will be
discussed below, and ethnicity. The association among MDM2
SNP309 and breast cancer and lung cancer is modiﬁed by ethnic
background, that is, the MDM2 SNP309 represents a risk factor for
breast cancer in Chinese women but not in non-Chinese women15
and is associated with lung cancer risk in Asians.16 This ethnic
difference can be explained at least partially by a second MDM2
SNP (SNP285 G4C; rs117039649) that can antagonize, as a C/G
variant, the effect of SNP309. This SNP285C/G reduces the binding
afﬁnity of the SP1 transcription factor.17 Interestingly, the SNP285C
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allele is absent in Asian populations (Han Chinese and Mon-
golians) and African Americans but is a pan-Caucasian variant that
occurs in approximately 6–8% of the Caucasian population and at
lower frequencies in Finns and Sami populations.18 Knappskog
and Lønning suggested that the studies performed on the
SNP285C-free Asian cohorts represent the ‘true’ effect of SNP309G,
whereas the studies in Western Europe need to be ‘corrected’ with
respect to SNP285 status.17
To date, MDM2 SNP309 studies are limited to an Asian-Japanese
cohort of renal cell carcinoma (RCC) patients.19 In this cohort,
Hirata and co-workers found increased MDM2 protein expression
in the tumors of G/G variant carriers, an elevated number of GG
carriers in a young patient group compared with a young healthy
control group (both ⩽ 64 years) and an 1.9-fold increased risk of
tumor-related death for G/G genotyped patients compared with
T/G+T/T patients. However, until now, the MDM2 SNP309 had not
been studied in a Caucasian cohort of RCC patients.
RESULTS AND DISCUSSION
In genotyping our unselected cohort of 197 Caucasian RCC
patients for MDM2 SNP309, we detected the G/G variant in 18
(9.1%) patients, the G/T variant in 116 (58.9%) patients and the T/T
variant in 63 (32.0%) patients (Figure 1). Among the 80 included
female RCC patients, 8 (10.0%) carried the G/G variant, 50 (62.5%)
carried the G/T variant and 22 (27.5%) carried the T/T variant. The
117 male RCC patients displayed the G/G variant in 10 (8.5%)
patients, the G/T variant in 66 (56.4%) patients and the T/T variant
in 41 (35.0%) patients (Table 1). The distribution of the genotypes
did not differ among histomorphological subtypes, tumor grades
or tumor stages (Table 1).
Next, we looked for an association between age at tumor onset
and SNP309 genotype. We did not detect an association within
the entire unselected RCC cohort or the male RCC patient
subcohort (data not shown). However, female RCC patients with a
G/G genotype were diagnosed 13.5 years earlier (median age 59.5
years) than those with a T/T genotype (median age 73 years;
Table 2). When the female RCC patients were divided into
age-related groups on the basis of median age at diagnosis
(i.e., ⩽ 68 years vs 468 years), genotype distributions differed
signiﬁcantly. We found 7 G/G patients and 1 G/G patient and 9 T/T
patients and 13 T/T patients in the young and the elder
female groups, respectively (P= 0.024; χ2-test; Table 1). This was
comparable with the earlier ﬁndings of Bond et al., who described
an association involving the SNP309G allele (G/C and G/G) in
colorectal cancer patients, with an average age difference of
9 years at tumor diagnosis9 and a 12-year age difference at tumor
onset in soft tissue sarcoma patients, which was restricted to
females.7
Bond et al.10 developed a model of the gender-related effect of
SNP309G/G based on estrogen receptor α (ERα) expression. It is
known that ERα induces MDM2 transcription.20 Interestingly, ERα
binds close to SNP309 in the MDM2 P2 promoter. This binding is
directly affected by the binding of the Sp1 transcription factor.
This leads to the model in which the G-allele of SNP309 can
accelerate tumorigenesis in the presence of an active estrogen
signaling pathway. The model is supported by the ﬁnding that the
G-allele of SNP309 is only associated with an earlier age of onset in
high ER-positive but not ER-negative intraductal breast cancer
patients.10
To study the age-related effect on tumor onset in more detail,
we investigated a second age-selected cohort of 205 Caucasian
RCC patients. This cohort encompassed a high proportion of
patients who had contracted RCC at an extraordinary young or old
age (o45 or 475 years, respectively). The G/G variant was
detected in 31 (15.1%) patients, the G/T, in 85 (41.5%) patients,
and the T/T, in 89 (43.4%) patients (Table 3). Among the 83 female
RCC patients, the G/G variant was detected in 13 (15.7%) patients,
the G/T variant, in 36 (43.3%) patients, and the T/T variant, in 34
(41%) patients; in the 122 male RCC patients, the G/G variant was
found in 18 (14.7%) patients, the G/T variant in 49 (40.2%) patients,
and the T/T variant in 55 (45.1%) patients (Table 3). Interestingly, in
this selected patient cohort, we found signiﬁcant differences in
SNP309 genotype distribution between the lower tumor stages
(pTa+pT1+pT2) and the higher tumor stage (pT3) and lower tumor
grades (G1+G2) and the higher tumor grades (G3+G4) (P = 0.039
and 0.004, respectively). Notably, the G/G genotype occurred
more frequently in the lower tumor grade and lower tumor stage
RCC patients (Table 3). However, the percentage of G/G variants
was only slightly elevated in the younger age group (⩽68 years)
compared with the elder group (468 years) of female patients, at
18.8% in the younger age group vs 14.9% in the elder group. We
most likely did not see an accumulation of younger female
patients in the G/G genotype group because in this cohort, only
28 females were included in the younger age group (⩽68 years),
and only 5 females carried the G/G genotype. However,
remarkably, the percentage of the G/G genotype was greater in
the male patients in the younger age group (⩽67 years) compared
Figure 1. Sequencing of MDM2 SNPs 285 and 309. Sequencing of MDM2 SNP 285 was performed as described in Spiegelberg et al.26 using
PCR sense primer 5′-TGGACTGGGGCTAGGCAGTC-3′ and antisense primer 5′CTGAGTCAACCTGCCCACTG3′ at a 62.9 °C annealing temperature.
The PCR product size was 248 bp and also encompassed the neighboring MDM2 SNP309 region. The sequencing result is shown for an RCC
sample. Sequencing of SNP285 showed a G/G homozygous (sense strand) and, correspondingly, a C/C homozygous (antisense strand)
genotype. Sequencing of SNP309 revealed a T/T homozygous (sense strand) and, accordingly, an A/A homozygous (antisense strand)
genotype.
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with the elder age group (467 years), at 19.4% for males in the
younger age group vs 8.0% for males in the elder age group. This
result is somewhat surprising because, until now, only an age-
related effect in female tumor patients has been described in
relation to elevated ERα expression in G/G genotype female
patients. Our ﬁnding could be associated with a relatively high
number of male RCC patients (N= 100) below the age median of
67 years, but further studies in RCC and other male tumor patients
are necessary to conﬁrm this.
Next, we determined if the above-mentioned age-related effect
on tumor onset in the female RCC patients was affected by the
SNP285 genotype. For both cohorts, we studied the SNP285
genotype in 18 female RCC patients with the G/G SNP309
genotype. However, in all cases studied, we detected the wild-
type homozygous G/G genotype. Therefore, we cannot comment
on the effect of the SNP285C/G genotype on the age of tumor
onset in German RCC patients with the SNP309G/G genotype.
However, our ﬁnding of the wild-type SNP285 in conjunction with
the SNP309G/G genotype could be displaying the ‘true’ effect of
SNP309G/G and explain the signiﬁcant age difference in tumor
onset between the female G/G genotype patients and the female
T/T genotype patients, as Knappskog and Lønning suggested.17
Future studies including SNP285C/G genotyped female RCC
patients could clarify the effect of SNP285 in RCC patients.
Finally, what role could human MDM2 SNP309 play for RCC
patients? An eightfold higher MDM2 expression level was
reported in cancer cell lines by comparing SNP309G/G with
SNP309T/T carrying cell lines.7 Several articles described that
MDM2 upregulation is associated with decreased disease-speciﬁc
survival in RCC patients.21 Roberts et al.22 showed that in clear cell
RCC, after the loss of the von Hippel-Lindau tumor suppressor
protein, hypoxia-inducible factor 2alpha accumulated and led to
the MDM2-mediated suppression of p53. Accordingly, Nutlin 3, a
small molecular inhibitor of the MDM2–p53 interaction, restored
p53 function, induced growth arrest and senescence in RCC cells
and reversed the resistance of RCC cells to Fas-mediated and
chemotherapy-induced cell death.22,23 In an RCC xenograft mice
model, the concurrent administration of the MDM2 (+MDM4)
antagonist MI-319 and sunitinib markedly increased the antitumor
and antiangiogenic activities of sunitinib, resulting in sustained
p53-dependent gene expression and signiﬁcantly reduced tumor
growth.24 The authors suggested that treatment with the MDM2
antagonist MI-319 could be an effective means of delaying or
preventing the development of sunitinib therapy resistance in
RCC.24 We suggest analyzing the MDM2 SNP309 genotype for
Table 2. Gender-speciﬁc median ages and distributions of SNP309
genotypes in the unselected cohort of RCC patients
RCC patients All SNP309
T/T T/G G/G
Females
Age in years:
median (range)
68 (48–89) 73 (55–84) 68 (48–89) 59.5 (55–83)
Males
Age in years:
median (range)
67 (46–91) 73 (35–91) 66 (39–88) 68.5 (44–81)
Female RCC patients with a G/G SNP309 genotype (median age 59.5 years)
were diagnosed 13.5 years earlier than the T/T females (median age
73 years), a difference that was statistically signiﬁcant. The signiﬁcance of
different genotype distributions among the patient groups was calculated
by the two-sided exact χ2-test using IBM SPSS Statistics 20 software
(SPSS-Science, Chicago, IL, USA). P-values o0.05 were regarded as
signiﬁcant.
Table 1. Clinicopathological parameters and human MDM2 SNP309
genotypes in the unselected cohort of RCC patients
Clinicopathological parameters No. of patients SNP309 P-valuea
Total T/T T/G G/G
Total 197 63 116 18
Gender 0.534
Females 80 22 50 8
Males 117 41 66 10
Morphology 0.453
Clear cell 181 61 103 17
Papillary 10 2 8 0
Chromophobe 5 0 4 1
Unknown 1 0 1 0
Age (years) 0.760
⩽ 67 101 30 61 10
467 96 33 55 8
Age (years)
Females 80
⩽ 68 43 9 27 7 0.077b
468 37 13 23 1 0.024c
Males 117 0.613
⩽ 67 62 21 37 4
467 55 20 29 6
Tumor stage 0.346
pTa 1 0 1 0
pT1 108 32 70 6
pT2 24 7 14 3
pT3 59 22 28 9
pT4 2 0 2 0
Unknown 3 2 1 0
Grouped tumor stage
pTa+pT1+pT2 133 39 85 9 0.082
pT3+pT4 61 22 30 9
unknown 3 2 1 0
Tumor grade 0.855
G1 30 9 19 2
G2 100 29 60 11
G3 62 22 35 5
Unknown 5 3 2 0
Grouped tumor grade
G1+G2 130 38 79 13 0.662
G3 62 22 35 5
Unknown 5 3 2 0
Age groups were separated by the medians (67 years for all RCC patients,
68 years for female RCC patients and 67 years for male RCC patients). DNA
from part of the unselected cohort (n= 137) and the age-selected cohort
was isolated from kidney specimens of patients who had undergone
surgery for RCC. For this purpose, normal kidney tissue of the highest
purity possible was needed. Therefore, three experienced uropathologists
(AH, SB and VS) marked tumor-free areas on hematoxylin and eosin
staining that had been obtained from formalin-ﬁxed and parafﬁn-
embedded tissues. Then, 5 μm sections from the respective specimens
were deparafﬁnized and manually microdissected after 15 s staining by
0.1% methylene blue using the marked hematoxylin and eosin staining as
a template. The purity of the obtained tumor-free kidney tissue was
near 100%. DNA from normal kidney tissue (n= 137) was isolated using the
Maxwell 16 LEV Blood DNA Kit (Promega Corporation Mannheim,
Germany) according to the manufacturer’s instructions. Furthermore, we
isolated DNA from the blood lymphocytes of additional RCC patients of
the unselected cohort (n= 60) as previously described.27 To genotype the
unselected cohort (n= 137) and the age-selected cohort (n = 205) for MDM2
SNP309, we used a restriction fragment length polymorphism approach as
summarized in Hitzenbichler et al.,28 whereby the unselected cohort was
analyzed on a 2.5% agarose/TAE gel instead of a capillary sequencing
system. In addition, genotyping of the other part of the unselected
cohort (n= 60) was performed as described previously.7 aCross tables,
χ2-test, signiﬁcant values are in bold face. bAll genotypes. cGenotypes
G/G vs T/T.
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an effect on sunitinib treatment in RCC patients in future
studies. Sunitinib treatment alone can increase p53 activity in
xenotransplants.24 The increased p53 activity may be affected by
different MDM2 expression levels depending on the SNP309
genotype.
Furthermore, the gender-speciﬁc effect of the SNP309G/G
variant may also have implications for estrogen signaling
manipulation in female RCC patients. An increase in estrogen
levels in postmenopausal women with the G/G variant could
increase their risk for other cancers such as soft tissue sarcomas,
colorectal cancers and ERα-positive invasive ductal breast
cancer,20 as well as RCC. On the other hand, female patients with
these cancers could beneﬁt from a reduction in ERα levels, as was
reported for invasive ductal breast cancer patients with high ERα,
for whom a decrease in ERα resulted in decreased tumor growth
and longer overall survival.20 However, the consequences of
estrogen receptor modulation have to be considered carefully, as
suggested by previous studies in breast cancer.25
The SNP309 has been studied in an Asian-Japanese RCC patient
group.19 The authors showed a signiﬁcant increase in the GG
genotype of the MDM2 SNP309 in RCC patients (31%) compared
with healthy controls (20%). However, we could not detect
signiﬁcant differences in the occurrence of the GG genotype
between the RCC patients and the healthy controls, nor could we
detect such a difference by separating RCC patients and healthy
controls by gender (the latter based on data from the literature;
Supplementary Table S1). However, the differences in the ﬁndings
of our study compared with the results of Hirata et al. could be
explained by ethnic differences between the Asian and Caucasian
populations. By comparing two age groups separated by a median
(⩽64 vs ⩾ 65 years), Hirata et al. reported a higher number of GG
genotype carriers in the younger patient group (30%) than in the
younger healthy control group (12%); however, this was not the
case when the patient group was compared with the control
group in the elder group. However, the authors did not see
signiﬁcant differences in the occurrence of the G/G genotype
between the younger and elder RCC patient groups without
distinguishing between female and male patients. We noted a
signiﬁcantly higher rate of G/G vs T/T genotypes in the younger
females (⩽68 years) compared with the elder female RCC patients
(468 years) (P= 0.024; χ2-test). However, we would have missed
detecting this difference by comparing G/G vs T/T genotype in a
joint female and male RCC cohort for both age groups (data not
shown), which may explain why our ﬁndings were different from
those of Hirata and co-workers. We analyzed overall survival data
for 189 RCC patients from the unselected study cohort and did not
detect a correlation between SNP309 genotype and survival, nor
was a correlation found when all RCC patients were separated
by gender (data not shown). Hirata et al. found a signiﬁcant
correlation between cancer-speciﬁc survival and the SNP309
genotype for the RCC patients in their study (N= 176) and noted
a worse prognosis for the G/G genotype patients vs the T/G+T/T
genotype patients (P = 0.0139). However, in our age-selected RCC
patient cohort the SNP309G allele occurred more frequently in the
lower tumor grade and the lower tumor stage groups than in
higher tumor grade and tumor stage groups. Whereas the latter
groups have a poorer prognosis (data not shown), which may
indicate that the G-allele is not associated with a worse outcome.
However, we suggest that the correlation between cancer-speciﬁc
survival and SNP309 genotypes in a Caucasian population of RCC
patients needs to be analyzed further in future studies.
In summary, female RCC patients of Caucasian origin with the
G/G variant of SNP309 in the human Mdm2 gene showed a
signiﬁcantly earlier age of tumor onset than female RCC patients
with the wild-type T/T genotype. The frequency of the SNP309
genotype should be tested, as should its association with tumor
onset and prognosis in additional RCC patient populations of
different ethnic origins. We suggest that the SNP309 genotype can
be considered useful for diagnostic and therapeutic approaches
for female RCC patients in the future.
ABBREVIATIONS
MDM2, murine double minute 2; RCC, renal cell carcinoma;
SNP, single-nucleotide polymorphism
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Table 3. Clinicopathological parameters and human MDM2 SNP309
genotypes in an age-selected second cohort of RCC patients
Clinicopathological
parameters
No. of
patients
SNP309 P-valuea
Total T/T T/G G/G
Total 205 89 85 31
Gender 0.884
Females 83 34 36 13
Males 122 55 49 18
Morphology 0.287
Clear cell 99 37 44 18
Papillary 29 15 11 3
Chromophobe 64 29 25 10
Othersb 13 8 5 0
Age (years) 0.473
⩽ 67 100 42 39 19
467 105 47 46 12
Age (years)
Females 83
⩽ 68 28 12 11 5 0.848
468 55 22 25 8
Males 122 0.861
⩽ 67 72 30 28 14
467 50 25 21 4
Tumor stage 0.421
pT1 122 45 55 22
pT2 30 12 13 5
pT3 49 28 17 4
Unknown 4 4 0 0
Grouped tumor stage
pTa+pT1+pT2 152 57 68 27 0.039
pT3 49 28 17 4
Tumor grade 0.052
G1 48 16 23 9
G2 124 50 54 20
G3 27 18 7 2
G4 6 5 1 0
Grouped tumor grade
G1+G2 172 66 77 29 0.004
G3+G4 33 23 8 2
The age groups were separated by the medians (67 years for all RCC
patients, 68 years for female RCC patients and 67 years for male RCC
patients). DNA from the age-selected cohort (n= 205) was isolated using
the High Pure PCR Template Preparation Kit (Roche Diagnostics Mannheim,
Germany). aCross tables, χ2-test, signiﬁcant values are in bold face. bThe
group others comprises malignant tumors with undifferentiated, mixed,
spindle cell morphology or Ductus-Bellini carcinoma.
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